(Q41063226)

26 September 2017

The coincidence of schizophrenia and Parkinsonism: some neurochemical implications (English)

1 reference

26 September 2017

0 references

parkinsonian syndrome

1 reference

2

Johnstone EC

1 reference

26 September 2017

Crow TJ

1

1 reference

26 September 2017

McClelleand HA

series ordinal

3

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 May 1976

1 reference

26 September 2017

Psychological Medicine

1 reference

26 September 2017

6

1 reference

26 September 2017

227-233

1 reference

26 September 2017

2

1 reference

Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs

26 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Drug-Induced Extrapyramidal Symptoms and Their Relations to Clinical Efficacy

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

SYKES TF: EXTRAPYRAMIDAL SIDE EFFECTS AND THERAPEUTIC RESPONSE.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

A comparison of the therapeutic and toxic effects of thioridazine and chlorpromazine in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Experimental neurological syndromes and the new drug therapies in psychiatry

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Psychiatric aspects of the post-encephalitic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Chlorpromazie and Dopamine: Conformational Similarities that Correlate with the Antischizophrenic Activity of Phenothiazine Drugs

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

An anatomy of schizophrenia?

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

1 reference

https://api.crossref.org/works/10.1017%2FS0033291700013763

7 January 2021

10.1017/S0033291700013763

Identifiers

DOI

0 references

1 reference